The American Journal of Surgery
Volume 196, Issue 4 , Pages 505-511 , October 2008

Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

Received 22 April 2008 ,Revised 3 June 2008

References 

  1. Cheek J, Lacy J, Toth-Fejel S, et al. The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg. 2002;137:1015–1019
  2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243–3253
  3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059
  4. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55:103–115
  5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am J Statistics. 1958;53:457–481
  6. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg. 2007;31:1041–1046
  7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  8. Adjuvant! Online. Accessed May 26, 2008. http://www.adjuvantonline.com
  9. Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol. 2007;196:342e1–342e9
  10. In:  Ries LAG,  Young JL,  Keel GE, et al. editor. SEER Survival Monograph: Cancer Survival Among Andults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. Bethesda, MD: National Institutes of Health; 2007;
  11. Bonnier P, Bessenay F, Sasco AJ, et al. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer. 1998;79:278–282
  12. Manjer J, Malina J, Berglund G, et al. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer. 2001;92:919–922
  13. Biglia N, Sgro L, Defabiani E, et al. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol. 2005;31:467–472
  14. Sacchini V, Zurrida S, Andreoni G, et al. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol. 2002;9:266–271
  15. In:  Greene FL,  Page D,  Fleming ID editor. AJCC Cancer Staging Manual. Ed 6. New York, NY: Springer; 2002;
  16. Antoine C, Liebens F, Carly B, et al. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial. Hum Reprod. 2004;19:741–756
  17. Planas-Silva MD, Waltz PK, Kilker RL. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant. J Steroid Biochem Mol Biol. 2006;98:193–198
  18. Lewis JS, Osipo C, Meeke K, et al. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol. 2005;94:131–141
  19. Prempro. Philadelphia, PA: Wyeth; 2007;[package insert]

 Dr. Rodney Pommier and Dr. SuEllen Pommier are consultants for Wyeth Pharmaceuticals.

PII: S0002-9610(08)00488-1

doi: 10.1016/j.amjsurg.2008.06.023

The American Journal of Surgery
Volume 196, Issue 4 , Pages 505-511 , October 2008

Article Tools

* Image Usage & Resolution